Century Therapeutics (IPSC) Total Non-Current Liabilities (2024 - 2026)

Century Therapeutics (IPSC) has 3 years of Total Non-Current Liabilities data on file, last reported at $59.9 million in Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities fell 10.2% year-over-year to $59.9 million in Q1 2026; TTM through Mar 2026 was $59.9 million, a 10.2% decrease from a year earlier, with the FY2025 full-year figure at $61.0 million, down 66.68% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $59.9 million, down from $61.0 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for IPSC reached as high as $185.0 million in Q2 2024 and fell as low as $59.2 million in Q3 2025.
• Historically, Total Non-Current Liabilities has averaged $115.0 million across 3 years, with a median of $66.7 million in 2025.
• Across the five-year window, Total Non-Current Liabilities tumbled 67.79% in 2025 and retreated 10.2% in 2026, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $183.1 million in 2024, then sank by 66.68% to $61.0 million in 2025, then fell by 1.87% to $59.9 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $59.9 million in Q1 2026, $61.0 million in Q4 2025, and $59.2 million in Q3 2025.